Plavix clopidogrel regulatory update

Sanofi said in its 3Q12 earnings that Japan approved sNDAs for Plavix clopidogrel to treat patients with peripheral artery disease (PAD) and with ST-elevated myocardial infarction. The product is already approved in Japan to treat stable angina/old myocardial infarction in patients undergoing percutaneous coronary interventions (PCI), reduce vascular event risk in patients with acute coronary syndrome with planned PCI and reduce the reoccurrence of stroke after ischemic cerebrovascular disorder. ...